期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗癌药凡德他尼的合成 被引量：3

Synthesis of anticancer drug vandetanib
下载PDF
导出
摘要 目的合成凡德他尼(vandetanib)并改进其合成工艺。方法以N-Boc-4-哌啶甲醇为起始原料,经磺化、缩合、N-甲基化、硝化、还原、环合、氯化、胺化反应制得凡德他尼。结果所得产物经元素分析、核磁共振谱及质谱等确证了结构。结论改进后的合成路线操作简单,收率高,易于实现工业化。 Objective To synthesize vandetanib and optimize the process. Methods Vandetanib was synthesized by steps of sulfonation,condensation, N-methylation,nitrification, reduction, cyclization, chlorination and amination. Results Chemical structure of vandetanib was conformed by element analysis, 1H-NMR and ESI-MS, etc. Conclusion A more reasonable operational path for the manufacturing process of vandetanib was provided by this experiment.
作者 刘宇 夏超 刘媛
机构地区 南京工业大学江苏省药物研究所有限公司
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2011年第12期917-920,共4页 Chinese Journal of Antibiotics
关键词 抗癌药 凡德他尼 合成 Anticancer drug Vandetanib Synthesis
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献4

  • 1Blixt J, Golden M D, Hogan P J, et al. Chemical Process: WO 2007/036713A2[P], 2005-09-30.
  • 2Laurent F H, Elaine S E S, Andrew P T, et al. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors[J]. J Med Chem, 2002, 45: 1300-1312.
  • 3Zampieri D, Grazia M M, Laurini E, et al. Substituted benzo[d]oxazol-2(3H)-one derivatives with preference for the sigmal binding site[J]. Eur J Med Chem, 2009, 44: 124-130.
  • 4Yann S, Michael E P, Johannes C, et al. Fluorine-18 labeling of 6,7- disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors: Synthesis of 18F-Iressa and related molecular probes[J]. J Lab Comp Radiopharm, 2005, 48: 829-843.

同被引文献30

  • 1张兰平.口服抗癌药Vandetanib[J].药学进展,2007,31(4):190-192. 被引量：3
  • 2Jorgen B, David G M, John H P, et al. Chemi- cal process: WO, 2007 36713 [ P]. 2007-04- 05.
  • 3Thomas G G, Sepehr S, Manoucherhr S. Sub- stituted quinazoline inhibitors of growth factor receptor tyrosine kinases : WO, 2010 028254 [P]. 2010-03-11.
  • 4Hennequin L F, Stokes E, Thomas A P, et al. Novel 4-Anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF recep- tor tyrosine kinase inhibitors [ J ]. Joumal of Medicinal Chemistry, 2002, 45 ( 6 ) : 1300- 1312.
  • 5Laurent Francois Andre H, Elaine Sophie Eliza- beth S, Andrew Peter T. Preparation of 4-anili- no-7-piperidinyloxy quinazolines as vascular en- dothelial growth factor inhibitors: WO, 2001 032651 [P]. 2001-05-10.
  • 6Tasler S, Mtiller O, Wieber T, et al, Substitu- ted 2-arylbenzothiazoles as kinase inhibitors: Hit-to-lead optimization [ J]. Bioorganic & Me- dicinal Chemistry, 2009, 17(18) : 6728-6737.
  • 7Wang T, Lui A S, Cloudsdale L S. A novel route to pyrrolo [ 2,1 -c ] [ 1,4 ] benzodiazepin-5- ones. formal total synthesis of ( + )-DC-81 [J]. Org Lett, 1999, 1 (11) :1835-1837.
  • 8Kamal A, Markandeya N, Shankaraiah N, et al, Chemoselective aromatic azido reduction with concomitant aliphatic azide employing A1/ Gd triflates/naI and ESI-MS mechanistic stud- ies [ J ]. Chemistry --A European Journal 2009, 15(29) : 7215-7224.
  • 9Hennequin L F, Thomas A P, Johnstone C, et al. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors[J]. J Med Chem, 1999, 42 (26), 5369-5389.
  • 10ASTRAZENECA PLC. FDA approves orphan drug vandeta- nib [EB/OL]. [2011-04-07]. http://www.astrazeneca.com/ Media/Press-releases/Article/20100407-fda-approves-orphan- drug-vandetanib.

引证文献3

二级引证文献4

中国抗生素杂志
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部